Citius Pharmaceuticals Inc (CTXR)

[ash111]

October 11, presentation: 2 catalysts page 19.
1.Phase 3 Clinical Study,First Patient In.
2.FDA 2nd Study Mtg.

Pipeline in Progressive Stages
ü Phase 3
• Lead product (Mino-Lok) is a unique antibiotic lock therapy that salvages central lines in bacteremic patients, has been granted QIDP, and is in Phase 3. There is no approved competition nor any on the horizon. We estimate the market to be >$1 billion worldwide.
ü Phase 2
• Gastrointestinal product (topical hemorrhoid symptomatic treatment) Phase 2a completed with positive directional results showing improvement over components and vehicle. This product would be the only FDA approved Rx therapy for hemorrhoids. Market is >4 million Rxs and we estimate the dollar market to be >$1 billion in US.
ü Targeted Acquisitions
• Business development activity focused on adjunctive cancer care (infection, chronic pain, nausea, etc.). Fast growing segment with exceptional opportunities.

https://ir.citiuspharma.com/presentations